Highlights
- Telix (ASX:TLX) reported Q3 2026 Revenue of USD 245 million.
- Precision Medicine quarterly revenue increased 30% year on year.
- Pixclara received US FDA approval for glioma imaging.
- Telix reaffirmed its FY26 revenue and other-income expectations.
Telix Pharmaceuticals Limited develops and commercialises radiopharmaceutical products for cancer imaging and treatment, with operations spanning precision medicine, therapeutic development and manufacturing. As at November 16, 2026, Telix (ASX:TLX) traded at AUD 13.555, down 0.18% during the session. Its September-quarter update described growth in imaging revenue, the introduction of another approved diagnostic product and a proposed transaction involving radioisotope supplier ITM.
Radiopharmaceutical Imaging and Therapy
Telix (ASX:TLX) markets prostate cancer imaging products Illuccix and Gozellix in the United States, alongside Pixclara for glioma imaging following its 2026 regulatory approval. The company also conducts clinical development programmes for other diagnostic applications and targeted radionuclide therapies. Radiopharmaceutical operations depend on isotope access, Manufacturing and distribution networks because some products require time-sensitive preparation and delivery.
Its Precision Medicine Business contains commercial imaging products, while Therapeutics develops investigational treatments that remain subject to Clinical Trials and regulatory review. Telix Manufacturing Solutions supports production and distribution activities, including the RLS network. Approval of one product does not constitute authorisation for the company’s separate development-stage candidates.
September-Quarter Developments
Telix reported US Food and Drug Administration approval of Pixclara for glioma imaging, with first commercial doses administered in September 2026. It also reported completion of enrolment in the BiPASS Phase 3 study of a prostate cancer diagnostic approach, involving 350 patients. The US regulator granted Fast Track Designation and supported a new drug application pathway, although these steps do not amount to approval of the proposed indication.
In September, the company announced a proposed combination with Isotope Technologies Munich, known as ITM. The announced agreement included upfront consideration of USD 1.65 billion on a cash-free, debt-free basis, with additional milestone-based consideration possible. Telix (ASX:TLX) stated that Shareholder approval and other closing conditions remained outstanding, with a shareholder meeting scheduled for December 1, 2026.
Q3 Financial Performance and Sector Context
Group revenue for the September 2026 quarter reached USD 245 million, compared with USD 206 million in the corresponding 2025 quarter, an increase of 19%. Revenue was USD 247 million in the immediately preceding quarter, meaning a 1% sequential decline. Precision Medicine revenue increased 30% year on year to USD 201 million, broadly unchanged from the prior quarter’s USD 202 million.
Telix Manufacturing Solutions generated USD 44 million in third-quarter revenue, compared with USD 47 million one year earlier and USD 45 million in Q2 2026. Product mix, Demand and distribution activity can influence quarterly comparisons. The company specified that its third-quarter financial data were unaudited, which is important when contrasting quarterly disclosures with audited annual financial statements.
Telix (ASX:TLX) reaffirmed expectations for FY26 revenue and other income to exceed USD 1 billion, with revenue tracking toward the upper end of its USD 950–970 million guidance range plus USD 40 million in other income. It also narrowed the FY26 Research and Development spending guidance range to USD 240–260 million, from USD 230–270 million.
Risks to Consider
Commercial radiopharmaceutical operations rely on production quality, logistics, clinical demand, reimbursement and product approvals. Investigational therapies face uncertain trial results and regulatory timelines. The proposed ITM transaction adds approval, financing and integration considerations. Telix must also manage research spending alongside its commercial portfolio, and its forecast figures remain subject to the assumptions described by management.
What to Watch Next
Relevant milestones include the ITM shareholder vote, further Pixclara commercial deployment and planned clinical and regulatory submissions. The company also described ongoing enrolment and development work across prostate, kidney and brain cancer programmes. Future disclosures can show whether commercial imaging revenue, manufacturing operations and research expenditure are developing within the stated FY26 guidance ranges.
Key Insights
Telix (ASX:TLX) reported year-on-year Q3 revenue growth led by Precision Medicine and expanded its approved diagnostic portfolio through Pixclara. The proposed ITM transaction and several clinical programmes remain dependent on further steps. Guidance, clinical progress and implementation of its manufacturing plans provide defined monitoring points.






Please wait processing your request...